Lunit invites you to their event

AI as an independent reader for screening mammograms

About this event


đŸ—’ïžAbout this presentation

During Eusobi 2023, Dr. Karin Dembrower presented the results of the ScreenTrustCAD study, led by Capio S:t Görans Hospital and Karolinska Institute. This study aims to assess the performance of an AI algorithm (Lunit INSIGHT MMG) combined with radiologists(s), compared to the standard-of-care of two radiologists assessing screening mammograms. Based on the results of the study, Capio S:t Görans Hospital became the world's first breast center to implement AI as an independent reader.

👉 Read the study published in the Lancet Digital Health: click here


📌Highlights

  • Prospective and population-based trial (55,581 women), conducted in real-world clinical settings
  • Based on the results, Lunit INSIGHT MMG to assist Capio S:t Görans' screening center in reading 65,000+ mammographies per year as an independent reader


📱 About the Speaker: Dr. Karin Dembrower


  • Head Physician at the department of Breast Radiology at Capio Sankt Göran Hospital
  • Board-certified specialist in general radiology, Department of Breast Radiology, Capio Sankt Göran Hospital, Stockholm, Sweden


🛑 Lunit INSIGHT MMG

Lunit INSIGHT MMG is an AI solution that detects breast cancer on mammograms with 96% accuracy.

Validated by studies published in the Lancet Digital Health, JAMA Oncology, and many more, Lunit INSIGHT MMG can improve your diagnostic performance, especially for dense breasts as well as detect breast cancers earlier.

Based on its proven accuracy, you can reduce false-negative cases and recall rates, which ultimately can address the shortage of breast specialists in a single and double-reading environment.

Hosted by

  • Team member
    T
    Team Lunit Lunit

Lunit

Conquer Cancer through AI

With an accuracy rate of 96-99%, our AI can empower you to achieve the highest level of accuracy in finding cancer and critical findings.

Lunit AI for chest x-ray and 2D & 3D mammography has been validated through 160+ studies and is now in use in over 2,300 sites globally.